dimanche 28 février 2021

E Ink and LTS Partner to Develop Smart Patch to Improve Medical Management

Par Rédaction , dans Communiqués , le 15 novembre 2017

Monday, October 23rd 2017 at 1:00pm UTC

Smart Patch Offers a Simpler Way for Patients to Administer and
Monitor Medicine Intake

BILLERICA, Mass.–(BUSINESS WIRE)– E Ink Holdings, « E Ink » (8069.TW), the leading innovator of electronic
ink technology and LTS Lohmann-Therapie Systeme AG, “LTS” leading in the
development and manufacturing of transdermal therapeutic systems, today
announced their partnership to develop a “Smart Patch” prototype. The
Smart Patch prototype is a transdermal therapeutic system (TTS) that
delivers medication to patients in a convenient, controlled and
comfortable manner and features an E Ink display to deliver and convey
relevant information about patch performance.

This press release features multimedia. View the full release here:

The “Smart Patch” prototype features an E Ink display to convey relevant information about patch per ...

The “Smart Patch” prototype features an E Ink display to convey relevant information about patch performance to patients. (Photo: E Ink Holdings)

According to a report conducted by the New England Healthcare Institute
(NEHI), poor medication adherence is a pervasive problem that costs $290
billion a year in the U.S. Forgetting to take medication and not
understanding administration instructions are among the main reasons why
between 20 and 50 percent of patients are not adhering to their medical
regimens. Smart drug systems like Smart Patches will increase globally
to nearly $81.4
billion by 2024
as they provide a more targeted, uniform and secure
method of drug delivery.

“Poor medical adherence negatively impacts patients’ therapeutic
outcomes, leading to more hospitalizations and higher total costs,” said
Dr. Hanshermann Franke, Corp. VP of R&D at LTS. “The main purpose of any
innovation must be centered on the idea of making patients’ lives as
healthy and comfortable as possible. This can be achieved by designing
“smart” solutions that easily integrate, facilitate treatment monitoring
and help patients use their medication properly.”

The Smart Patch is equipped with a 2” E Ink electronic paper display
(EPD) that leverages the display’s bistable nature to ensure the patient
doesn’t need to recharge the battery. The patch features a switch,
pressure sensor and a low voltage E Ink display that shows helpful
information with functionalities including:

  • A message indicating whether the patch is applied correctly to the skin
  • A countdown until the next dose
  • A reminder to remove the patch and to replace it appropriately

“This is the first application to feature E Ink’s low voltage film,
which uses 50-70 percent of the typical driving voltage for EPDs,” said
Dr. FY Gan, EVP of Sales Center at E Ink. “In addition to minimizing
power consumption, which results in the ability to use a small battery
with a longer battery life, the low voltage film is the thinnest
electronic paper film available on the market at less than 200um,
enabling it to fit flawlessly on the TTS.”

“There are many advantages to TTS technologies, and now we can add a
decisive enhancement – an E Ink display,” said Dr. Tim Schlange, CMO at
LTS. “This feature allows LTS to provide functionalities to patients
with more reliable, safe and pain-free applications and to further
enhance the value of solutions for its partners in the pharmaceutical

“Medical innovation is happening at an unprecedented rate and we are
excited to partner with a company that is providing unique drug delivery
systems in the marketplace to improve medical compliance,” said Dr. Paul
Apen, Chief Strategy Officer at E Ink. “Our displays are a natural fit
for this type of drug delivery system as they are thin, have a wide
viewing angle and consume minimal power for continued use. This is just
one of the ways our display technology is impacting the future of
medical applications.”

The Smart Patch concept will initially target the treatment of chronic
diseases. The first prototype will be displayed during CPhI in Messe
Frankfurt, Germany October 24-26, 2017 at LTS’s booth 4.0 C40.

For more information or to speak with a sales representative, visit www.EInk.com.

About E Ink Holdings

E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media
Lab, has transformed and defined the eReader market and is redefining
the signage, architecture and design, mobile, wearable and retail
markets with its ePaper technology, enabling a new multi-billion dollar
market in less than 10 years. Its corporate philosophy aims to deliver
revolutionary products, user experiences and environmental benefits
through advanced technology development. This vision has led to its
continuous investments in the field of ePaper displays as well as
expanding the use of its technologies into a number of other markets and
applications including smart packaging and fashion. Its Electrophoretic
Display products make it the worldwide leader for ePaper. Its Fringe
Field Switching (FFS) technologies are a standard for high-end LCD
displays and have been licensed to all major liquid crystal display
makers in the world. Listed in Taiwan’s Taipei Exchange (TPEx) and the
Luxembourg market, E Ink Holdings is now the world’s largest supplier of
ePaper displays. For more information please visit www.eink.com.

About LTS Lohmann Therapie Systeme AG

LTS is a leading pharmaceutical technology company that develops and
manufactures innovative drug delivery systems such as Transdermal
Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical
industry. LTS’s innovation model consists of both partner-funded and
self-funded initiatives currently encompassing more than 20 marketed
products and a deep and diverse pipeline of development projects
targeting multiple disease indications. LTS maintains its leading
position through the continuous refinement of its core TTS and OTF
technologies and by advancing emerging drug delivery technologies,
including Micro Array Patches for the transdermal delivery of large
molecule, biological actives. Founded in 1984, LTS operates today from
two sites in Andernach, Germany and West Caldwell, NJ, USA and a
representation in Shanghai, China.


E Ink:
Racepoint Global
Ginsberg, +1 617-624-3254
Marketing und Market Services
Dr. Iris Schnitzler, +49 (0) 2632 99
– 2589

Source: E Ink Holdings

Étiquettes :